Halozyme Therapeutics, Inc. (NASDAQ:HALO) in last trading activity moved down -0.25% to close at $16.06. Company weekly performance is 2.75% while its quarterly performance stands at 110.21%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) is -2.96% away from its 52 week high. On 10 March, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported that Genmab A/S announced plans for a Phase 1 clinical trial of a subcutaneous formulation of the anti-CD38 antibody daratumumab using the ENHANZE™ technology.
Cerulean Pharma Inc. (NASDAQ:CERU) in last trading activity moved up 15.49% to close at $10.66. Company weekly performance is 33.42% while its quarterly performance stands at 73.33%. Cerulean Pharma Inc. (NASDAQ:CERU) is 9.90% away from its 52 week high. Cerulean Pharma Inc. (NASDAQ:CERU) announced that a Phase 1b/2 trial of its lead nano particle-drug conjugate, CRLX101, in combination with Avastin® in relapsed renal cell carcinoma (RCC) achieved its primary endpoint of at least 50% of patients achieving four months of progression free survival (PFS).
On last trading day Mercury Systems, Inc. (NASDAQ:MRCY) moved up 0.75% to close at $16.21. Its volatility for the week is 2.02% while volatility for the month is 2.06%. MRCY’s sales growth for past 5 years was 2.00% and its EPS growth for past 5 years was -18.90%. Mercury Systems, Inc. (NASDAQ:MRCY) monthly performance is -5.76%. On 16 March, Mercury Systems, Inc. (NASDAQ:MRCY) announced that its Mercury Defense Systems (MDS) subsidiary has received $2 million in follow-on orders to deliver advanced Digital RF Memory (DRFM) jammers to the U.S. Navy.
Ophthotech Corporation (NASDAQ:OPHT) has 14.30% insider ownership while its institutional ownership stands at 92.80%. In last trading activity company’s stock closed at $53.00. On 10 March, Ophthotech Corporation (NASDAQ:OPHT) announced that it has achieved a second $50 million enrollment milestone from Novartis Pharma AG as part of the ex-US licensing and commercialization agreement between the two companies focused on the treatment of wet age-related macular degeneration (AMD).
On last trading day UMB Financial Corporation (NASDAQ:UMBF) moved up 0.60% to close at $51.83. Its volatility for the week is 2.04% while volatility for the month is 2.35%. UMBF’s sales growth for past 5 years was 0.40% and its EPS growth for past 5 years was 3.60%. UMB Financial Corporation (NASDAQ:UMBF) monthly performance is 0.14%. UMB Financial Corporation (NASDAQ:UMBF) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a research note issued to investors on Tuesday. The firm currently has a $52.60 price target on the stock. Zacks‘s price target would suggest a potential upside of 1.92% from the company’s current price.